The Dermatology Digest

APRIL 25, 2025

The BLA submission is supported by data from more than 2,100 patients treated with TrenibotE in the clinical program, which included two pivotal Phase 3 clinical studies evaluating TrenibotE for the treatment of moderate to severe glabellar lines (M21-500 and M21-508) and a Phase 3 open-label safety study (M21-509).

Treatments 36

Treatments Clinic Safety Innovations 36

The Dermatology Digest

MARCH 10, 2025

improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. “These results also continue to validate Protagonist’s innovative peptide technology platform and its effectiveness in creating highly differentiated new chemical entities to address unmet needs in various disease areas.”

Safety 36

Safety Medical Innovations Dermatology 36

The Dermatology Digest

OCTOBER 30, 2024

Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

Sun Protection 36

Sun Protection Dermatology Safety Innovations 36

The Dermatology Digest

MARCH 3, 2025

We are excited to be able to provide DEB patients with the first treatment that corrects the genetic defect and makes a true difference in their lives, says Cristina Has, MD, Professor and Head of the Genodermatoses Clinic in the Department of Dermatology at the University of Freiburg in Germany, in a news release.

Therapy 36

Therapy Clinic Hospital Dermatology 36

The Dermatology Digest

NOVEMBER 6, 2024

” The TBA recipients include: Innovating Pain and Fatigue Management Cynthia Aranow, MD, The Feinstein Institutes for Medical Research Dr. Aranow will evaluate the use of a new, non-toxic, non-painful device that stimulates the vagus nerve to reduce pain and fatigue in people with SLE.

Hospital 36

Hospital Therapy Management Networking 36

The Dermatology Digest

FEBRUARY 18, 2025

I am looking forward to offering my patients this new treatment option which has the potential to address their most troublesome symptoms, says Curdin Conrad, MD, a Professor of Dermatology and Head of Policlinic and the center for psoriasis at Lausanne University Hospital in Switzerland, in a news release.

Dermatitis 36

Dermatitis Marketing Hospital Clinic 36

The Dermatology Digest

FEBRUARY 2, 2024

New sunscreen ingredients are needed to help assuage patient safety concerns and lower skin cancer rates. Natural products such as algae and herb derivatives are also gaining traction, according to a new narrative review in the Journal of Integrative Dermatology. Innovations in Sunscreen Filters: What is on the Horizon in the US?

Ingredients 74

Ingredients Safety Innovations Dermatology 74

The Dermatology Digest

APRIL 17, 2024

“Advancing the standard of care within aesthetic medicine requires us to discover and develop novel innovations into products with strong safety profiles and meaningful patient impact,” says Darin Messina, Ph.D., Senior Vice President, Aesthetics R&D, AbbVie, in a news release.

Webinar 74

Webinar Safety Innovations Dermatology 74

The Dermatology Digest

MAY 16, 2024

Sonelokimab is being assessed in two lead indications, HS and psoriatic arthritis (PSA), and the Company is pursuing other indications in dermatology and rheumatology. The safety profile of sonelokimab in the ARGO trial was consistent with previous trials with no new safety signals detected.

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

MAY 16, 2024

Emma Guttman-Yassky, MD, PhD , the Waldman Professor and Chair of Dermatology at Icahn Mount Sinai and the Mount Sinai Health System in New York City, has been awarded a new $6.6 NIH Grant to Study Dupilumab in Pediatric AA appeared first on The Dermatology Digest. PHOTO CREDIT: DermNet The post Mount Sinai Awarded $6.6M

Eczema 69

Eczema Dermatitis Clinic Safety 69

The Dermatology Digest

FEBRUARY 14, 2024

We are one step closer to delivering this innovative solution to those in need and look forward to the outcomes of these filing decisions.” Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

MARCH 14, 2025

Novartis is the ideal partner to help us in this mission due to their unparalleled expertise in innovative medicines and their dedication to improving health outcomes,” adds Chief Medical Officer at the NFL, Dr. Allen Sills.

Pharmaceutical 36

Pharmaceutical Partnerships Medical Office 36

The Dermatology Digest

FEBRUARY 26, 2024

This represents a crucial step in offering a potential innovative treatment option to patients and their dedicated physicians, addressing a condition that is often under-recognized, under-treated and significantly impacts patients’ lives.” Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, in a news release.“

Office 74

Office Clinic Safety Innovations 74

Dermatology Times

APRIL 18, 2025

James Song, MD, FAAD, discusses how emerging topical JAK inhibitors like ruxolitinib cream may reduce the necessity for systemic therapies in select pediatric atopic dermatitis patients by effectively controlling moderate disease and potentially serving as long-term maintenance therapy with a favorable safety profile.

Therapy 36

Therapy Innovations Dermatitis Safety 36

The Dermatology Digest

MARCH 5, 2024

“The approval of JUVÉDERM VOLUMA XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs,” says Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie, in a news release. “This is the first U.S. .

Portfolios 74

Portfolios Injections Training Facials 74

The Dermatology Digest

SEPTEMBER 9, 2024

“These formulations enhance overall skin texture, underscoring our commitment to integrating cutting-edge scientific research and ingredients into practical, effective skincare solutions,” says Eman Kadhim, Head of Scientific Communications & Upstream Innovation at Waldencast, in a news release.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

JUNE 14, 2024

ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile. The data was presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

FEBRUARY 5, 2024

“We are honored to be recognized for the 2024 People’s Choice Award by Octane’s esteemed judges, entrepreneurs and experts in dermatology and plastic surgery,” says Dina El-Sherif, MBA, founder and CEO of Trufacial, in a news release (Pictured above).

Dermatology 36

Dermatology Pharmaceutical Technology Sales 36

New Age Spa Institute

OCTOBER 12, 2023

link] Peter Thomas Roth Italian American Skincare entrepreneur and founder of Peter Thomas Roth skincare brand, known for innovative solutions. It integrates the industry’s most potent laser-emitting diode with an innovative double cooling system that utilizes copper and gold macrochannels.

Hair Removal 52

Hair Removal Skin Types Skincare Brands Technology 52

The Dermatology Digest

AUGUST 30, 2024

The safety profile of pembrolizumab in this trial was consistent with the drug’s established safety profile. The primary endpoint is RFS, and key secondary endpoints include OS and safety. The post Keytruda Disappoints in Phase III SCC Trial; Merck Halts Study appeared first on The Dermatology Digest.

Surgery 36

Surgery Safety Therapy Innovations 36

The Dermatology Digest

MAY 14, 2024

The American Skin Association’s (ASA) SPOTS (Sun Protection Outreach Teaching by Students) program will receive the inaugural 2024 Research Achievement Award in Community Education/Outreach at the upcoming 2024 Society for Investigative Dermatology (SID) Annual Meeting in Dallas, TX. ” ASA Chairman, Howard P.

Sun Protection 36

Sun Protection Partnerships Education Safety 36

The Dermatology Digest

JANUARY 30, 2024

The Pediatric Dermatology Research Alliance (PeDRA) has awarded nearly $240K to support pediatric dermatology research across four competitive grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

US Dermatologt Partners

MARCH 27, 2024

Red light therapy is considered one of the newest and most innovative skin rejuvenation procedures available. Dermatology Partners in Cedar Park, Texas , “ Red light therapy is so new that the dermatologic community hasn’t even settled on one name for it. Safety and Side Effects This procedure is considered safe.

Therapy 41

Therapy Treatments Dermatology Collagen 41

The Dermatology Digest

SEPTEMBER 27, 2024

The safety profile of deucravacitinib in PSORIATYK SCALP was consistent with findings in previously conducted clinical trials of deucravacitinib in psoriasis. Overall, these promising results reinforce once-daily Sotyktu as a potential oral standard of care as we continue to lead in TYK2 innovation.” versus 9.8%), pain (26.2%

Clinic 36

Clinic Safety Dermatology Treatments 36

The Dermatology Digest

DECEMBER 27, 2023

2023 Highlights December 2023: The SOCS Meeting the Challenge Summit: Population Descriptors in Dermatology Research Studies. and L’Oréal Research & Innovation (Champion Level); Bristol Myers Squibb, Eli Lilly, Inc., August 2023: Dermatology Foundation and SOCS Partner to Advance Health Equity in Dermatology.

Education 36

Education Innovations Dermatology Clinic 36

The Eco Well Blog

MAY 16, 2022

Next up, we’ll be tackling the topic of safety, coming your way in late September. IBA supports creative, innovative companies from startups to established multinational businesses of all sizes succeed in the rapidly changing, highly competitive global cosmetics and personal care industry. in both Skin Care and Hair Care.

Legal 52

Legal Pharmaceutical Sun Protection Technology 52

The Dermatology Digest

MARCH 5, 2024

The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients.

Injections 36

Injections Safety Sustainability Clinic 36

Aesthetic Advancements Institute (AAI)

MAY 15, 2023

Tattoo: The Latest Innovation One of the latest and most promising stretch mark treatments are inkless tattoos and medical stretch mark camouflage. So let’s embrace our bodies and offer our patients the opportunity to achieve confidence with these stretch mark treatments while offering innovation in the aesthetic field.

Treatments 36

Treatments Microdermabrasion Skin Anatomy Scarring 36

The Dermatology Digest

DECEMBER 14, 2023

The post Meet the 2023 NEA Grant Winners appeared first on The Dermatology Digest. Ofir Cohn PhD , Boston Children’s Hospital, Boston, MA Deciphering how genetic variation associated with risk of eczema impacts human dendritic cell subset function Liwen Deng BS, PhD , President & Fellows of Harvard College, Boston, MA S.

Eczema 36

Eczema Dermatitis Hospital Networking 36

Enlightened Beauty

AUGUST 2, 2024

While many clean beauty products do use natural ingredients, the focus is really on safety and effectiveness. It's like having a brainy best friend vet your products for ingredient safety and transparency. It's all about finding that sweet spot between safety and effectiveness. Another myth?

Ingredients 52

Ingredients Branding Comedogenic Makeup 52

Aesthetic Advancements Institute (AAI)

JUNE 20, 2023

Expert Opinions on Volux According to Dr. Hadley King , a New York City-based board-certified dermatologist and clinical instructor of dermatology at the Weill Medical College of Cornell University, “Volux has more structure and cohesivity and lift capacity” than other Juvéderm fillers, such as Voluma XC.

Training 36

Training Injections Medical Facials 36

The Dermatology Digest

OCTOBER 5, 2023

“It all boils down to stress,” said Keira Barr, MD, who presented “Beauty & The Beast: Stress, Trauma, Skin Disease & A Somatic Approach to Healing,” during the “Mind Body Therapies as Treatment Strategy in Dermatology: What is the Evidence?” ” session at the 2023 AAD Innovation Academy in Tampa, Florida. “I

Safety 36

Safety Social Media Therapy Sun Protection 36

West Lake Dermatology

OCTOBER 16, 2023

This innovative technology offers a convenient solution to the hassle of constant shaving or waxing and can be performed on various body areas such as the legs, armpits, chest, arms, and bikini area. Laser hair removal should be performed by trained and licensed professionals to ensure safety and effectiveness.

Hair Removal 36

Hair Removal Waxing Technology Skin Types 36

Aesthetics Advisor

JUNE 16, 2024

Exosomes, neurocosmetics, and supercharged actives are the most innovative — and sometimes the most controversial — skin-care trends poised to revolutionize beauty in the next few years. But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.” freeze) them.

Injections 36

Injections Aromatherapy Ingredients Moisturization 36

West Lake Dermatology

JANUARY 10, 2025

This comprehensive guide will help you recognize red flags, ask the right questions, and prioritize your safety. In the US, legitimate practitioners often hold certifications from reputable organizations like the American Board of Plastic Surgery (ABPS) or American Academy of Dermatology (AAD).

Legal 36

Legal Injections Safety Ethics 36

The Dermatology Digest

MAY 17, 2024

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. patient-years (PYs) for the safety analyses. Year 4, 0.1)

Safety 36

Safety Sustainability Clinic Innovations 36